Nadofaragene Firadenovec-Vncg
Last Updated: 04/28/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 20 publications
Current use of pre-clinical models for evaluation of human adenovirus-based cancer therapeutics.
Journal: Molecular therapy. Oncology
Published: February 06, 2026
Intravesical gemcitabine (Inlexzo) for bladder cancer.
Journal: The Medical letter on drugs and therapeutics
Published: October 21, 2025
Gene-mediated therapy for BCG-unresponsive nonmuscle-invasive bladder cancer: mechanisms, clinical evidence, and practical implementation.
Journal: Current opinion in urology
Published: September 19, 2025
Intravesical interferon-α2b gene therapy with nadofaragene firadenovec-vncg: a contemporary review.
Journal: Future oncology (London, England)
Published: July 10, 2025
Use of Rectal Diazepam to Prevent Bladder Spasms and Leakage of Medication During Intravesical Administration of Nadofaragene Firadenovec for Bacillus Calmette-Guérin-Unresponsive Nonmuscle-Invasive Bladder Cancer.
Journal: The Journal of urology
Published: June 26, 2025
Real-world outcomes of nadofaragene firadenovec for BCG-unresponsive non-muscle-invasive bladder cancer: A multicenter experience.
Journal: Urologic oncology
Published: May 22, 2025
Practical use of nadofaragene firadenovec-vncg for pharmacists.
Journal: Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners
Published: February 18, 2025
FDA Approval Summary: Nadofaragene Firadenovec-vncg for Bacillus Calmette-Guérin-Unresponsive Non-Muscle-Invasive Bladder Cancer.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: August 28, 2024
Recent Advances in Drug Delivery Strategies for High-Risk BCG-Unresponsive Non-Muscle Invasive Bladder Cancer: A Brief Review from 2018 to 2024.
Journal: Pharmaceutics
Published: July 30, 2024
In brief: Anktiva for bladder cancer.
Journal: The Medical letter on drugs and therapeutics
Published: June 21, 2024
An evaluation of nadofaragene firadenovec-vncg for the treatment of high-risk BCG-unresponsive non-muscle-invasive bladder cancer.
Journal: Expert opinion on biological therapy
Published: June 11, 2024
Efficacy of Intravesical Nadofaragene Firadenovec for Patients With Bacillus Calmette-Guérin-Unresponsive Nonmuscle-Invasive Bladder Cancer: 5-Year Follow-Up From a Phase 3 Trial.
Journal: The Journal of urology
Published: May 05, 2024
Last Updated: 04/28/2026